Pharmacy Times
NOVEMBER 4, 2023
Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.
STAT
NOVEMBER 4, 2023
Today STAT turns 8. In these annual letters, I usually talk proudly about all we have accomplished, from our singular coverage of the Covid pandemic to our years-in-the-making court victory to force Purdue Pharma to release documents about its OxyContin marketing efforts, to our success at becoming the go-to media outlet covering health and medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
NOVEMBER 4, 2023
Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.
Drug Topics
NOVEMBER 4, 2023
A poster presented at AMCP Nexus 2023 outlined how a Pharmacy Therapeutics program yielded $7,500 in savings per patient and $3.5 million in savings overall by reducing patients' incretin therapy prescriptions from two to one.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
NOVEMBER 4, 2023
Awdishu describes the implementation of new equations to accurately drug dose in patients as well as provide updated guidance on the dosing of older medications.
Board Vitals - Pharmacist
NOVEMBER 4, 2023
Ah, the holidays – the season of giving. It’s the time of year when patients want to express their gratitude for your care with gifts that may range from the ridiculous to the sublime. They are all given with good intentions, but should you accept them? And if you do, are all gifts created equal? Is a tin of cookies the same as a gift certificate or a day of golf?
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmacy Times
NOVEMBER 4, 2023
Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
Melpida is under clinical development by Elpida Therapeutics and currently in Phase II for Paraplegia.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Expert insights. Personalized for you.
145 
Let's personalize your content